| HS Code | 907941 |
| Name | Small Interfering RNA |
| Abbreviation | siRNA |
| Type | double-stranded RNA |
| Length | approximately 21-23 nucleotides |
| Mechanism | RNA interference |
| Function | gene silencing |
| Origin | synthetic or endogenous |
| Target | messenger RNA (mRNA) |
| Application | gene knockdown experiments |
| Mode Of Delivery | transfection |
| Specificity | sequence-specific |
As an accredited Small Interfering RNA factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Small Interfering RNA, 1 mg, supplied in a sterile 1.5 mL RNase-free microcentrifuge tube; clearly labeled; cold-packaged. |
| Shipping | Small Interfering RNA (siRNA) is shipped in lyophilized form, typically at room temperature or with cold packs, depending on the product and destination. Packaging ensures protection from moisture and temperature fluctuations. Upon arrival, siRNA should be stored at -20°C or as recommended to maintain stability and activity. |
| Storage | Small Interfering RNA (siRNA) should be stored at -20°C to -80°C in a nuclease-free environment to maintain stability and prevent degradation. Store the siRNA lyophilized or in RNase-free water or buffer. Avoid repeated freeze-thaw cycles, and aliquot if necessary. siRNA solutions should be kept tightly sealed, protected from light, and handled with gloves to prevent RNase contamination. |
Our manufacturing-grade small interfering RNA (siRNA) supports advanced downstream innovation across multiple sectors. The following application scenarios reflect only the most established commercial and industrial integration of siRNA, with each segment based upon validated protocols and regulatory frameworks relevant to their respective end-products.
Commercial-scale therapeutic manufacture utilizes siRNA as a key active ingredient in gene-silencing-based drug products, particularly for rare genetic and chronic disorders. Downstream manufacturers rely on controlled formulation and stringent process integration to meet the highest regulatory thresholds, ensuring both product safety and reproducibility at each batch release step. Our siRNA supports direct incorporation into injectable formulations, nanoparticle-based drug delivery systems, and lyophilized active pharmaceutical ingredients.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Seed developers and crop protection companies leverage siRNA to modulate gene expression for pest resistance and yield enhancement. Formulators embed siRNA within plant-compatible carriers, deploying it through foliar sprays, seed coating, or root drench processes. The adoption of siRNA biopesticides and RNA-enabled trait delivery aligns with rising regulatory scrutiny regarding genetic manipulation and environmental safety in agriculture.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Diagnostic kit producers incorporate siRNA in functional genomics tools and reference materials for clinical laboratories. siRNA enables endogenous gene knockdown in cell-based assays or acts as control reagents in qRT-PCR kits, supporting test accuracy in infectious disease or cancer biomarker screening. Manufacturers adhere to stringent lot release and contamination control procedures to meet global clinical diagnostics market standards.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Industrial cell therapy and recombinant protein producers utilize siRNA to modulate host cell gene expression, mitigating problematic pathways or modulating metabolic activity during large-scale culture. In bioprocessing, siRNA supports transient knockdown protocols to improve batch yield, protein quality, or cell viability, particularly in CHO or HEK293 production systems. Downstream integration governs batch consistency, biosafety, and traceability as required for regulated biologics manufacturing.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Animal health product developers employ siRNA as active agents for the treatment of viral and genetic diseases in companion and livestock species. Manufacturers formulate siRNA with carrier nanoparticles or biodegradable gels, integrating them into injectable or oral dosage forms. Process validation must ensure compliance with veterinary-specific safety and efficacy guidelines, supported by stability and uniformity testing before batch release.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive Small Interfering RNA prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Every day in our production facility, expertise builds right alongside our batches of small interfering RNA, or siRNA for short. This isn’t a product that rolled out of a generic catalog: years spent refining our synthesis processes show in every order, thanks to solid, repeatable chemistry and real-world problem-solving. Our siRNA products take shape from a combination of high-precision solid-phase synthesis and consistent in-process controls, tightened up from hundreds of feedback loops with scientists who use them at the bench.
The best siRNA doesn’t shout its presence; it works quietly, targeting specific messenger RNA in cells and knocking down gene expression with reliability. Our standard duplexes run 21 nucleotides long, with sharply defined antisense and sense strands. We deliver these with two-base 3’ overhangs, usually dTdT, a structure that fits most cell transfection protocols and matches the natural Dicer processing route in mammalian systems.
Our strength lies in control and detail: we regularly test for purity (HPLC and mass spec confirmation), sequence accuracy, and salt form. You won’t find unresolved trityl groups or persistent synthesis byproducts in our vials. Over hundreds of runs, we’ve found customers return for consistent yields, typically 5, 10, or 20 nanomole scale, meeting research size as well as pilot preclinical needs. We keep side chain deprotection and desalting chemistry clean. The result is an oligonucleotide ready for transfection that doesn’t throw surprises into your controls.
Anyone who’s tried to silence a gene in mammalian cells knows the value of dependable reagents. Researchers use our small interfering RNA to temporarily block messenger RNA targets, shutting down protein expression. Most customers send us gene targets based on published siRNA sequences, but a growing group prefers custom designs—sometimes based on our algorithmic services, sometimes coming from their own bioinformatic screens. Either way, efficient knockdown often needs a few candidates; our synthesis lines support positive and negative controls, scrambled sequences, and labeled duplexes all within the same batch window.
Every researcher’s workhorse these days is the 21-mer siRNA, chosen for balance between potency and off-target reduction. Cells treated with our duplexes usually show clear knockdown in as little as 24-48 hours post-transfection. Transfection-ready salts ship dried, allowing you to resuspend in the buffer or medium suited to your protocol, minimizing degradation risk during shipment and handling.
Through years of technical support, we’ve seen the usual headaches: difficult gene targets, secondary structure in target RNAs, worries about innate immune triggers. We respond with design tips and solid product data, not just claims. For knockdown in human, mouse, or rat cell lines, our sequences follow the usual rules for minimal off-targets and immuno-stimulatory motifs.
Some siRNA vendors chase scale with automated equipment but let quality slip in the rush. We run our facility with oversight at every step: reagents come in with proper certification, and we track each step of synthesis, cleavage, deprotection, and purification. Each batch gets HPLC data, documented yields, and identity confirmation by mass spectrometry before we release it.
In practice, the extra work on purification pays off. End-users see this in lower background in RNA interference assays, little to no cytotoxicity in cell culture, and a high signal-to-noise ratio when running qPCR or Western blot validation after knockdown. We screen for critical contaminants, including process-derived inorganic salts and residual solvents, to safeguard your downstream assays.
We’ve answered panicked calls from labs plagued by unexplained cell toxicity or inconsistent results—the culprit often traces back to poorly purified oligos or sequences with incomplete deprotection. Those working at the benchtop understand how a missed detail from synthesis can cost a week’s worth of work or more. That’s the context shaping every improvement we roll out.
One challenge in oligonucleotide synthesis is flexibility—different targets, organism backgrounds, or delivery methods. Our production setup flexes with your needs. Standard siRNA is available unmodified, but we keep a menu of modifications ready: 2’-O-methyl or 2’-fluoro sugar substitutions for stability, cholesterol tags for delivery, biotin or fluorescent labels for tracking, and backbone modifications to knock down innate immune activation.
Diagnostic clients trust us for FAM and Cy5-labeled duplexes for imaging. Pharma partners sometimes specify locked nucleic acids or phosphorothioate linkages for animal studies. Our synthesis and purification pipelines accommodate these, with full mass spec profiles included. Custom modifications get the same QA handling as our catalog duplexes.
Labs face a confusing market: shRNA, esiRNA, antisense oligos, siRNA. Each tool has its place. Our siRNA matches the need for fast, transient, sequence-specific knockdown in basic research and early validation. Unlike long dsRNA, our duplexes avoid triggering broad innate immune responses in mammalian cells. The carefully designed 21-23mer size range reflects what actually clears in customer hands—maximizing knockdown with minimal non-specific toxicity.
We often field questions from labs comparing our siRNA to shRNA or CRISPRi constructs. Plasmid-based shRNA can give stable, long-term knockdown but demands cell line creation, antibiotic selection, and far more time. siRNA, on the other hand, delivers results overnight and leaves the genome untouched. CRISPRi, though potent, is overkill for quick protein function confirmation, brings in complicated vectors, and can pose delivery issues.
We’ve supplied both classic and chemically modified siRNAs into direct cytosolic transfection, electroporation, and in vivo delivery studies. For animal experiments, customers appreciate the extra chemical tailoring (modifications for nuclease resistance or enhanced tissue distribution) and our response in scaling synthesis to milligram quantities when pilot data moves to proof-of-concept studies.
Our partnership with users shapes what we deliver. One oncology group shared that only our duplexes produced a complete knockdown of KRAS—an outcome their previous off-the-shelf oligos missed. Another neuroscience lab saw cleaner suppression of synaptic protein in hippocampal slice cultures, thanks to our improved desalting and strict post-synthesis cleanup. These field reports feed our cycle of testing and optimization.
Not every siRNA sequence behaves predictably; highly structured mRNA targets or high GC content can complicate knockdown. In these cases, we support with sequence redesign and batch reruns. We’ve increased the robustness of our design tools, relying on rules tested in mammalian, plant, and insect systems. Our team keeps up with the shifting understanding of off-target processes, including microRNA context and seed sequence spillover, updating algorithms and sharing best practices with returning customers.
With delivery methods evolving, we now routinely supply siRNA composed for nanoparticle, liposome, or conjugate-driven targeting. Our QC standards don’t ease up when batches grow or when deadlines tighten for larger animal pilot studies; metrology, lot tracking, and contamination profiles remain strict. Human error gets minimized through automation where prudent, but always overseen by chemists who troubleshoot on the spot.
Chemical manufacturing can be a dirty business unless careful. Our oligonucleotide synthesis avoids bulk use of toxic solvents where possible. We manage solid-phase waste, hazardous organics, and spent reagents using modern recovery and neutralization systems. Our operations follow strict local and international regulations, well beyond what compliance checklists demand. Any customer-specific handling advice reflects what we’ve validated on our own floor—transport stability, long-term storage, disposal options for unused material.
We focus not just on internal safety: the packaging and transport of our siRNA always follow verified cold chain protocols for bulk or temperature-sensitive shipments. Vials get delivered with clear labeling, cap color coding, and secure, tamper-evident seals, avoiding the mix-ups that can haunt multi-plate experimental runs.
Every chemist in our facility has answered technical support emails for customers troubleshooting delivery or knockdown—sometimes late nights, always direct feedback. This cycle helps us keep track of new vectors, better cationic lipids, or alternate solvent systems labs move to. We provide side documentation: full validation data, protocols, RNase-free suggestions, and even references to literature supporting specific chemical modifications or design rules.
Direct-to-user manufacturing changes the dynamic: customer requests funnel feedback directly to the lab, not through layers of paperwork or middlemen. Labs grappling with secondary structure or sequence-dependent toxicity issues get human answers, not auto-generated text.
The field keeps moving. As therapeutic and agricultural gene silencing expand, demand pushes for longer, more modified, and more stable RNA reagents. We respond by collaborating directly with biotech partners and startup developers, integrating emerging chemical modifications and responsive design kits into our synthesis lines. Work on self-delivering or temperature-stable siRNA feeds directly into new workflows in clinical or field settings.
We expect solutions to long-standing delivery hurdles—especially targeted or tissue-specific RNAi—to drive the next jump in siRNA demand. Our role as a manufacturer is to keep tools simple, chemistry strong, and service accessible. Problems and questions flow straight to our floor, fueling honest debugging and faster iteration.
Seeing research groups run the same siRNA campaign months or years apart, using our product, and getting the same results, gives us a front-row seat to the ways chemistry supports discovery. Universities, drug development labs, and bioscience startups come back with the next gene, trust the preparation, and don’t spend energy second-guessing batch-to-batch drama. Consistency shows up as data reproducibility—the cornerstone of all science, and something that stands out in a crowded marketplace.
Manufacturers carry the responsibility for getting the chemistry right, but also for listening. Every time we run into a technical hurdle, we document, we share, and we update procedures. Full traceability on sequence, chemical modifications, and batch origin isn’t an add-on; it’s our normal. Lab-to-lab feedback improves designs, catches hidden pitfalls, and drives honest progress.
siRNA will keep evolving. Direct communication and repeatable, high-quality chemistry keep research moving forward with less downtime and more confidence in the data—straight from the source, with both feet planted squarely on the factory floor.
